Summary
This 2024 ESMO clinical practice guideline presents an interim update on first-line therapeutic options for advanced urothelial carcinoma, synthesising evidence from randomised trials and expert consensus to inform standardised treatment selection. As a normative guidance document rather than primary empirical research, it is intended to support evidence-based decision-making across European and international oncology centres. The guideline addresses both immunotherapy and chemotherapy modalities within the context of contemporary trial evidence and clinical practice.
UK applicability
This guideline is directly applicable to UK oncology practice, as ESMO guidelines are widely adopted by the National Institute for Health and Care Excellence (NICE) and UK cancer networks to inform treatment pathways. UK centres managing advanced urothelial carcinoma would use such consensus guidance to align practice with European standards.
Key measures
Not applicable—this is a normative clinical guideline rather than an empirical study with outcome metrics.
Outcomes reported
The guideline presents an interim update on first-line therapeutic strategies for advanced urothelial carcinoma, synthesising evidence on immunotherapy and chemotherapy approaches. It does not report empirical outcome measures but rather provides expert-consensus recommendations for treatment selection.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.